RESORT研究(E4402)长期随访:两种利妥昔单抗给药策略治疗低肿瘤负荷滤泡性淋巴瘤的随机III期比较
RESORT研究(E4402)将299例未治疗的低肿瘤负荷滤泡性淋巴瘤且对利妥昔单抗有应答的患者随机分配至再治疗利妥昔单抗(RR)策略或维持利妥昔单抗(MR)策略,每项策略持续至治疗失败。长期随访显示,7年时MR组83%无需首次化疗,RR组为63%(HR 2.37,95%CI 1.5-3.76),7年时MR组71%仍处于首次缓解,RR组为37%,但10年总生存无差异(83% vs 84%)。
要点
- 7年时MR组83%未需首次化疗,RR组63%(HR 2.37,95%CI 1.5-3.76)。
- 7年时MR组71%仍处于首次缓解,RR组37%。
- 10年总生存MR组83% vs RR组84%,无差异。
核心结论
- 长期成熟数据证实,延长维持利妥昔单抗未在低肿瘤负荷滤泡性淋巴瘤中带来总生存优势。
研究设计与样本
- 东部肿瘤协作组(ECOG)于2003年发起随机III期临床试验(E4402),比较两种利妥昔单抗给药策略。
- 对利妥昔单抗有应答的患者(n=299)随机分配至再治疗利妥昔单抗(RR)策略或维持利妥昔单抗(MR)策略。
- 每项给药策略持续至治疗失败,主要终点为至治疗失败时间(TTF)。
主要发现
- 7年时MR组83%未需首次化疗,RR组63%(HR 2.37,95%CI 1.5-3.76)。
- 7年时MR组71%仍处于首次缓解,RR组37%。
- 10年总生存MR组83% vs RR组84%,无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.In 2003, the Eastern Cooperative Oncology Group initiated a randomized phase III clinical trial (E4402) comparing two different rituximab dosing strategies for patients with previously untreated low-tumor burden follicular lymphoma. Rituximab-responsive patients (n = 299) were randomly assigned to either a retreatment rituximab (RR) strategy or a maintenance rituximab (MR) strategy. Each dosing strategy was continued until treatment failure. The primary end point of the study was time to treatment failure (TTF). In the original report, there was no difference in TTF between the two dosing strategies. Here, we report on the long-term outcomes for secondary end points of time to first cytotoxic therapy, duration of response, and overall survival (OS). At 7 years, 83% of MR patients had not required first chemotherapy compared with 63% of RR patients (hazard ratio, 2.37 [95% CI, 1.5 to 3.76]). At 7 years, 71% of MR remained in their first remission compared with 37% of RR patients. Despite the improved first remission length with MR, there was no difference in OS at 10 years (83% v 84%). With mature long-term data, we confirm that prolonged maintenance rituximab does not confer an OS advantage in low-tumor burden follicular lymphoma.
引用
- Kahl BS, Jegede OA, Peterson C, et al. Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma. J Clin Oncol. 2024. PMID: 38194625. doi:10.1200/JCO.23.01912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。